The cost-effectiveness of the early insulin use treatment pathway in the ADA/EASD joint consensus algorithm for the treatment of type 2 diabetes (T2D)

被引：0
|
作者：
Willis, Michael
Asseburg, Christian
Neslu-San, Cheryl
Persson, Ulf
机构：
来源：
DIABETES | 2008年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A98 / A98
页数：1
相关论文
共 50 条
  • [41] Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands
    van Haalen, Heleen G. M.
    Pompen, Marjolein
    Bergenheim, Klas
    McEwan, Phil
    Townsend, Rebecca
    Roudaut, Marina
    [J]. CLINICAL DRUG INVESTIGATION, 2014, 34 (02) : 135 - 146
  • [42] Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada
    Grima, Daniel T.
    Thompson, Melissa F.
    Sauriol, Luc
    [J]. PHARMACOECONOMICS, 2007, 25 (03) : 253 - 266
  • [43] Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands
    Heleen G. M. van Haalen
    Marjolein Pompen
    Klas Bergenheim
    Phil McEwan
    Rebecca Townsend
    Marina Roudaut
    [J]. Clinical Drug Investigation, 2014, 34 : 135 - 146
  • [44] The cost-effectiveness of pioglitazone in combination with metformin in the treatment of type 2 diabetes mellitus in Scotland
    Stynes, G
    Tilden, D
    Swift, M
    Cockle, S
    Haycox, A
    Aristides, M
    [J]. VALUE IN HEALTH, 2004, 7 (06) : 737 - 738
  • [45] COST-EFFECTIVENESS OF CANAGLIFLOZIN TREATMENT IN CHINESE PATIENTS WITH TYPE 2 DIABETES AND KIDNEY DISEASE
    Wu, B.
    [J]. VALUE IN HEALTH, 2019, 22 : S584 - S584
  • [46] Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain
    Pinol, Carme
    Roze, Stephane
    Valentine, William
    Evers, Thomas
    [J]. GACETA SANITARIA, 2007, 21 (02) : 97 - 104
  • [47] Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes
    Te Li
    Xu Wan
    Jin Ma
    Bin Wu
    [J]. Advances in Therapy, 2018, 35 : 2214 - 2223
  • [48] COST-EFFECTIVENESS OF ROSIGLITAZONE COMBINATION THERAPY FOR THE TREATMENT OF TYPE 2 DIABETES IN THE CZECH REPUBLIC
    Dolezal, T.
    Skoupa, J.
    Taylor, M. J.
    Whitehead, S.
    Rausova, V
    Pavlikova, P.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A504 - A504
  • [49] Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration
    McEwan, Phil
    Gordon, Jason
    Evans, Marc
    Ward, Thomas
    Bennett, Hayley
    Bergenheim, Klas
    [J]. MEDICAL DECISION MAKING, 2015, 35 (05) : 660 - 670
  • [50] Modelling Cost Effectiveness of Insulin Glargine for the Treatment of Type 1 and 2 Diabetes in Canada
    Daniel T. Grima
    Melissa F. Thompson
    Luc Sauriol
    [J]. PharmacoEconomics, 2007, 25 : 253 - 266
12345